Ratings by Morgan Stanley (Vikram Purohit)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/11/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/2/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2022 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 7/8/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/5/2022 | Talaris Therapeutics | TALS | Downgrade | Equalweight (Overweight) |
4.51 (4.10) |
-9.09% | Details | |
| 6/13/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/3/2022 | Instil Bio Inc | TIL | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/20/2022 | Foghorn Therapeutics | FHTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/6/2022 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2022 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/20/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/11/2022 | Exscientia PLC | EXAI | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/22/2022 | Regenxbio Inc. | RGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2022 | Talaris Therapeutics | TALS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2022 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/9/2022 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/19/2022 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/15/2021 | Foghorn Therapeutics | FHTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2021 | Radius Health | RDUS | Downgrade | Underweight (Equalweight) |
8.01 (10.08) |
25.84% | Details | |
| 11/19/2021 | Schrodinger | SDGR | Downgrade | Equalweight (Overweight) |
44.45 (28.00) |
-37.01% | Details | |
| 11/12/2021 | HOOKIPA Pharma Inc. | HOOK | Downgrade | Equalweight (Overweight) |
4.35 (1.56) |
-64.14% | Details | |
| 11/11/2021 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2021 | Sage Therapeutics | SAGE | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/26/2021 | Exscientia PLC | EXAI | New Coverage | Equalweight (N/A) |
22.20 (9.73) |
-56.17% | Details | |
| 10/19/2021 | Sage Therapeutics | SAGE | New Coverage | Equalweight (N/A) |
44.07 (42.20) |
-4.24% | Details | |
| 10/19/2021 | Regenxbio Inc. | RGNX | New Coverage | Overweight (N/A) |
35.38 (31.09) |
-12.13% | Details | |
| 10/19/2021 | Kaleido Biosciences Inc. | KLDO | Downgrade | Underweight (Equalweight) |
4.94 (0.29) |
-94.13% | Details | |
| 9/23/2021 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/16/2021 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 9/7/2021 | Theravance Biopharma | TBPH | Maintain | Underweight (N/A) |
|
Details | ||
| 8/25/2021 | Theravance Biopharma | TBPH | Downgrade | Underweight (Overweight) |
14.17 (9.32) |
-34.23% | Details | |
| 8/18/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/18/2021 | HOOKIPA Pharma Inc. | HOOK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2021 | Tscan Therapeutics Inc | TCRX | New Coverage | Overweight (N/A) |
10.46 (3.06) |
-70.75% | Details | |
| 8/10/2021 | Axsome Therapeutics | AXSM | Downgrade | Equalweight (Overweight) |
51.16 (59.26) |
15.83% | Details | |
| 7/16/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/1/2021 | Talaris Therapeutics | TALS | New Coverage | Overweight (N/A) |
15.12 (4.10) |
-72.88% | Details | |
| 5/26/2021 | Instil Bio Inc | TIL | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/26/2021 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/18/2021 | Radius Health | RDUS | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/18/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 5/13/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/4/2021 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/13/2021 | Instil Bio Inc | TIL | New Coverage | Equalweight (N/A) |
22.03 (5.76) |
-73.85% | Details | |
| 4/8/2021 | HOOKIPA Pharma Inc. | HOOK | New Coverage | Overweight (N/A) |
13.56 (1.56) |
-88.5% | Details | |
| 4/5/2021 | Incyte | INCY | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/22/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/22/2021 | Foghorn Therapeutics | FHTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/8/2021 | Certara Inc. | CERT | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 3/2/2021 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/1/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2021 | Pandion Therapeutics | PAND | Downgrade | Equalweight (Overweight) |
25.63 (60.05) |
134.3% | Details | |
| 2/10/2021 | Incyte | INCY | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/19/2021 | Kymera Therapeutics | KYMR | Maintain | Equalweight (Equalweight) |
|
Details | ||
| 1/6/2021 | Certara Inc. | CERT | New Coverage | Equalweight (N/A) |
33.00 (16.31) |
-50.58% | Details | |
| 11/9/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/14/2020 | Theravance Biopharma | TBPH | Upgrade | Overweight (Equalweight) |
17.62 (14.17) |
-19.58% | Details | |
| 8/25/2020 | Radius Health | RDUS | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/6/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/13/2020 | Radius Health | RDUS | Downgrade | Equalweight (Overweight) |
14.80 (10.08) |
-31.89% | Details | |
| 5/12/2020 | Incyte | INCY | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/29/2020 | Incyte | INCY | Downgrade | Equalweight (Overweight) |
102.98 (73.78) |
-28.36% | Details | |
| 4/1/2020 | Incyte | INCY | Upgrade | Overweight (Equalweight) |
72.17 (73.78) |
2.23% | Details | |
| 3/6/2020 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2020 | Unum Therapeutics | UMRX | Downgrade | Equalweight (Overweight) |
0.67 (2.35) |
250.75% | Details | |
| 2/28/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/10/2020 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/27/2019 | Unum Therapeutics | UMRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2019 | Neon Therapeutics | NTGN | Downgrade | Underweight (Overweight) |
1.35 (3.07) |
127.41% | Details | |
| 11/6/2019 | Portola Pharmaceuticals | PTLA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/11/2019 | Radius Health | RDUS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/5/2019 | Unum Therapeutics | UMRX | New Coverage | Overweight (N/A) |
1.69 (2.35) |
39.05% | Details | |
| 9/5/2019 | Radius Health | RDUS | New Coverage | Overweight (N/A) |
27.70 (10.08) |
-63.61% | Details | |
| 9/5/2019 | Neon Therapeutics | NTGN | New Coverage | Overweight (N/A) |
2.55 (1.35) |
-47.06% | Details | |
| 9/5/2019 | Portola Pharmaceuticals | PTLA | New Coverage | Equalweight (N/A) |
28.40 (18.03) |
-36.51% | Details | |
| 9/5/2019 | DBV Technologies S.A | DBVT | New Coverage | Equalweight (N/A) |
9.42 (2.40) |
-74.52% | Details |
